Attention Deficit Hyperactivity Disorder
Conditions
Keywords
methylphenidate, functional connectivity, graph theory, cognitive control
Brief summary
The purpose of this study is to test whether children with attention-deficit/hyperactivity disorder (ADHD) are impaired in the ability to flexibly adapt brain network organization in response to shifting cognitive demands during the exertion of cognitive control, by assessing changes in network dynamics resulting from stimulant administration in children with ADHD, and how those changes relate to behavioral and symptom improvements. Subjects will be children with ADHD aged 8-12. Subjects will participate in multiple testing sessions that include: diagnosis and eligibility screening, neuropsychological and behavioral testing, and, if eligible, MRI scans and a medication challenge. Children with ADHD who are enrolled in the medication challenge will undergo one MRI scan on placebo and one MRI scan on stimulant medication, counterbalanced and double-blind. Functional connectivity will be measured using functional MRI and innovative graph theoretical analytic tools will be implemented. Network metrics will be related to symptomatology and behavioral testing measures. It is hypothesized that stimulant administration in children with ADHD will increase flexibility in network reconfiguration in response to changing cognitive control demands as compared to when they are on placebo. It is further hypothesized that the degree to which brain network organization is changed will be related to the degree of improvement in cognitive control performance.
Interventions
A single, low dose of methylphenidate (0.3 mg/kg) will be administered on the drug day.
A matching placebo pill will be administered on the placebo day.
Sponsors
Study design
Masking description
The pharmacy that provides the drug/placebo works from a randomized subject order defining whether each subject received drug first or placebo first. Only the pharmacists know this order, and the drug and placebo look identical to the participants and the investigators.
Intervention model description
Randomized, double-blind, placebo-controlled, crossover design. Each subject with ADHD participates in two sessions, one on drug and one on placebo (order randomized ). Both subjects and experimenters are blind to the order.
Eligibility
Inclusion criteria
* Between 8-12 years old * Diagnosis of ADHD (for ADHD group); ADHD group only can have comorbid Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnoses of oppositional defiant disorder, conduct disorder, depressive disorders, or anxiety disorders * ADHD subjects must never have been treated with medication for their ADHD
Exclusion criteria
* Wechsler Intelligence Scale for Children-Fifth Edition Full-Scale Intelligence Quotient (IQ) \< 80 * Wechsler Individual Achievement Test-Third Edition Word Reading \< 85 * Any neurologic or developmental disabilities * Any reading or learning disabilities * Visual impairment that cannot be corrected-to-normal * Color blindness * Documented hearing impairment greater than 25 decibels (dB) loss in either year * Have already gone through puberty (Tanner Stage II or higher) * Medical contraindication to MRI * Any psychoactive medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Resting State Brain Network Organization | 1 to 3 hours after administration of intervention | Assessment of network topology during a resting state using functional connectivity estimates. Modularity will be determined by applying graph theoretical methods to functional connectivity estimates acquired during functional magnetic resonance imaging (fMRI) scans. Modularity is measured on a -1 to 1 scale, with higher scores indicating stronger community structure, or a stronger tendency of clusters of brain regions to separate into distinct, highly interconnected networks with sparse connections across networks. The optimal modularity value depends on the context. For example, during complex tasks lower modularity is better, while during basic, automatic tasks higher modularity is better. |
| Task-Based Brain Network Organization | 1 to 3 hours after administration of intervention | Assessment of network topology during the Go/No-go (GNG) regular and GNG reward tasks. Subjects see a series of sports balls and are told to respond to most balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Graph theoretical methods are applied to functional connectivity estimates from fMRI scans to determine modularity during each task. Modularity (-1 to 1 scale) measures the degree to which the whole-brain system separates into distinct communities, such that greater modularity reflects stronger community structure, or stronger tendency of brain regions to separate into distinct, highly interconnected networks with few connections across networks. Optimal modularity value depends on context. During complex tasks lower modularity is better, while higher modularity is better for basic tasks. |
| Rest-Task Reconfiguration | 1 to 3 hours after administration of intervention | Assessment of reconfiguration of network topology between the GNG regular task and the resting state and GNG reward task and resting state. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Normalized mutual information will be determined by applying the same graph theoretical methods to functional connectivity estimates acquired during fMRI scans for each rest-task pair. Normalized mutual information is measured on a 0 to 1 scale, with higher scores indicating more similarity in network structure across task and rest conditions. |
| Drug-induced Normalization | 1 to 3 hours after administration of intervention | Assessment of how changes in brain network topology relate to improvements in behavioral performance on the GNG regular and reward tasks, in which subjects respond to go stimuli and withhold responses to no-go stimuli. GNG tasks are identical, except subjects are rewarded for good performance on the reward task. Brain measures include change in modularity during rest, GNG regular, and GNG reward (Outcome Measures 1, 2); behavioral measures include change in commission rate, omission rate, and coefficient of variation of response time during GNG tasks (Outcome Measures 5-7). Pearson correlations are used to relate change in brain measures with change in behavioral measures from the placebo to the methylphenidate scans. Positive correlations indicate that subjects with greater change in the brain measure had greater change in the behavioral measure. Negative correlations indicate that subjects with less change in the brain measure had greater change in the behavioral measure. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Go/No-go (GNG) Omission Rate | 1 to 3 hours after administration of intervention | Evaluation of omission errors assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. In both tasks, omission errors occur on trials on which participants do not respond to a go stimulus to which they are supposed to respond. Omission errors are scored from 0 (no omission errors) to 1 (100% omission errors), with lower values indicating better performance. |
| Go/No-go (GNG) Response Time Variability | 1 to 3 hours after administration of intervention | Evaluation of response time variability assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Coefficient of variation (standard deviation / mean) will be calculated for response time in GNG regular and GNG reward tasks separately to account for group differences in mean response time. |
| Go/No-go (GNG) Commission Rate | 1 to 3 hours after administration of intervention | Evaluation of commission errors assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. In both tasks, commission errors occur on trials on which participants respond to a stimulus (go response) when they are supposed to withhold a response (no-go trial). Commission errors are scored from 0 (no commission errors) to 1 (100% commission errors), with lower values indicating better performance. |
Countries
United States
Participant flow
Recruitment details
Participants were recruited between December 2016 and March 2020.
Pre-assignment details
A total of 47 participants were screened during a behavioral visit. Of those not randomized, 8 did not meet inclusion criteria and 2 withdrew from study.
Participants by arm
| Arm | Count |
|---|---|
| Methylphenidate, Then Placebo Participants received a single, low dose of methylphenidate (0.3 mg/kg) before the first MRI scan. Approximately one week later, participants received a matching placebo pill before the second MRI scan. | 19 |
| Placebo, Then Methylphenidate Participants received a matching placebo pill before the first MRI scan. Approximately one week later, participants received a single, low dose of methylphenidate (0.3 mg/kg) before the second MRI scan. | 18 |
| Total | 37 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| First Intervention (2-4 Hours) | Unable to Swallow Pill | 0 | 1 |
| First Intervention (2-4 Hours) | Withdrawal by Subject | 0 | 1 |
Baseline characteristics
| Characteristic | Methylphenidate, Then Placebo | Placebo, Then Methylphenidate | Total |
|---|---|---|---|
| Age, Continuous | 9.71 years STANDARD_DEVIATION 0.92 | 9.75 years STANDARD_DEVIATION 1.41 | 9.73 years STANDARD_DEVIATION 1.17 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 1 Participants | 3 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 17 Participants | 16 Participants | 33 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 3 Participants | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 17 Participants | 14 Participants | 31 Participants |
| Region of Enrollment United States | 19 Participants | 18 Participants | 37 Participants |
| Sex: Female, Male Female | 9 Participants | 9 Participants | 18 Participants |
| Sex: Female, Male Male | 10 Participants | 9 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 35 | 0 / 36 |
| other Total, other adverse events | 11 / 35 | 9 / 36 |
| serious Total, serious adverse events | 0 / 35 | 0 / 36 |
Outcome results
Drug-induced Normalization
Assessment of how changes in brain network topology relate to improvements in behavioral performance on the GNG regular and reward tasks, in which subjects respond to go stimuli and withhold responses to no-go stimuli. GNG tasks are identical, except subjects are rewarded for good performance on the reward task. Brain measures include change in modularity during rest, GNG regular, and GNG reward (Outcome Measures 1, 2); behavioral measures include change in commission rate, omission rate, and coefficient of variation of response time during GNG tasks (Outcome Measures 5-7). Pearson correlations are used to relate change in brain measures with change in behavioral measures from the placebo to the methylphenidate scans. Positive correlations indicate that subjects with greater change in the brain measure had greater change in the behavioral measure. Negative correlations indicate that subjects with less change in the brain measure had greater change in the behavioral measure.
Time frame: 1 to 3 hours after administration of intervention
Population: Participants excluded due to excessive head motion (mean framewise displacement \[FD\] \> 0.5 mm or fewer than 150 timepoints remaining after scrubbing all timepoints with FD \> 0.2 mm), incomplete brain coverage, or poor-quality fMRI data. Participants excluded if incomplete behavioral GNG data. Must have good data from both scan days to be included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Methylphenidate | Drug-induced Normalization | Delta GNG reg mod vs delta GNG reg RT variability | -0.195 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta rest mod vs delta GNG reg commission rate | -0.361 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta rest mod vs delta GNG reg omission rate | 0.508 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta rest mod vs delta GNG reg RT variability | 0.287 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta rest mod vs delta GNG rew commission rate | 0.162 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta rest mod vs delta GNG rew RT variability | 0.003 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta rest mod vs delta GNG rew omission rate | -0.224 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta GNG reg mod vs delta GNG reg commission rate | -0.033 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta GNG reg mod vs delta GNG reg omission rate | -0.170 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta GNG rew mod vs delta GNG rew commission rate | 0.220 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta GNG rew mod vs delta GNG rew omission rate | -0.276 correlation coefficient |
| Methylphenidate | Drug-induced Normalization | Delta GNG rew mod vs delta GNG rew RT variability | -0.027 correlation coefficient |
Resting State Brain Network Organization
Assessment of network topology during a resting state using functional connectivity estimates. Modularity will be determined by applying graph theoretical methods to functional connectivity estimates acquired during functional magnetic resonance imaging (fMRI) scans. Modularity is measured on a -1 to 1 scale, with higher scores indicating stronger community structure, or a stronger tendency of clusters of brain regions to separate into distinct, highly interconnected networks with sparse connections across networks. The optimal modularity value depends on the context. For example, during complex tasks lower modularity is better, while during basic, automatic tasks higher modularity is better.
Time frame: 1 to 3 hours after administration of intervention
Population: Participants excluded due to excessive head motion (mean framewise displacement (FD) \> 0.5mm or fewer than 150 timepoints remaining after scrubbing all timepoints with FD \> 0.2mm), incomplete brain coverage, or poor-quality fMRI data. Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Methylphenidate | Resting State Brain Network Organization | 0.223 units on a scale | Standard Deviation 0.026 |
| Placebo | Resting State Brain Network Organization | 0.228 units on a scale | Standard Deviation 0.034 |
Rest-Task Reconfiguration
Assessment of reconfiguration of network topology between the GNG regular task and the resting state and GNG reward task and resting state. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Normalized mutual information will be determined by applying the same graph theoretical methods to functional connectivity estimates acquired during fMRI scans for each rest-task pair. Normalized mutual information is measured on a 0 to 1 scale, with higher scores indicating more similarity in network structure across task and rest conditions.
Time frame: 1 to 3 hours after administration of intervention
Population: Participants excluded due to excessive head motion (mean framewise displacement \[FD\] \> 0.5mm or fewer than 150 timepoints remaining after scrubbing all timepoints with FD \> 0.2mm), incomplete brain coverage, or poor-quality fMRI data. Participants must have good data from both scan days and all tasks being compared to be included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Methylphenidate | Rest-Task Reconfiguration | GNG reward | 0.122 units on a scale | Standard Deviation 0.074 |
| Methylphenidate | Rest-Task Reconfiguration | GNG regular | 0.104 units on a scale | Standard Deviation 0.055 |
| Placebo | Rest-Task Reconfiguration | GNG regular | 0.119 units on a scale | Standard Deviation 0.058 |
| Placebo | Rest-Task Reconfiguration | GNG reward | 0.150 units on a scale | Standard Deviation 0.074 |
Task-Based Brain Network Organization
Assessment of network topology during the Go/No-go (GNG) regular and GNG reward tasks. Subjects see a series of sports balls and are told to respond to most balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Graph theoretical methods are applied to functional connectivity estimates from fMRI scans to determine modularity during each task. Modularity (-1 to 1 scale) measures the degree to which the whole-brain system separates into distinct communities, such that greater modularity reflects stronger community structure, or stronger tendency of brain regions to separate into distinct, highly interconnected networks with few connections across networks. Optimal modularity value depends on context. During complex tasks lower modularity is better, while higher modularity is better for basic tasks.
Time frame: 1 to 3 hours after administration of intervention
Population: Participants excluded due to excessive head motion (mean framewise displacement \[FD\] \> 0.5mm or fewer than 150 timepoints remaining after scrubbing all timepoints with FD \> 0.2mm), incomplete brain coverage, or poor-quality fMRI data. Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Methylphenidate | Task-Based Brain Network Organization | GNG regular | 0.213 units on a scale | Standard Deviation 0.041 |
| Methylphenidate | Task-Based Brain Network Organization | GNG reward | 0.235 units on a scale | Standard Deviation 0.051 |
| Placebo | Task-Based Brain Network Organization | GNG regular | 0.218 units on a scale | Standard Deviation 0.04 |
| Placebo | Task-Based Brain Network Organization | GNG reward | 0.213 units on a scale | Standard Deviation 0.055 |
Go/No-go (GNG) Commission Rate
Evaluation of commission errors assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. In both tasks, commission errors occur on trials on which participants respond to a stimulus (go response) when they are supposed to withhold a response (no-go trial). Commission errors are scored from 0 (no commission errors) to 1 (100% commission errors), with lower values indicating better performance.
Time frame: 1 to 3 hours after administration of intervention
Population: Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis. Participants included if they completed at least one task.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Methylphenidate | Go/No-go (GNG) Commission Rate | GNG regular | 0.396 units on a scale | Standard Deviation 0.213 |
| Methylphenidate | Go/No-go (GNG) Commission Rate | GNG reward | 0.292 units on a scale | Standard Deviation 0.176 |
| Placebo | Go/No-go (GNG) Commission Rate | GNG regular | 0.403 units on a scale | Standard Deviation 0.206 |
| Placebo | Go/No-go (GNG) Commission Rate | GNG reward | 0.348 units on a scale | Standard Deviation 0.181 |
Go/No-go (GNG) Omission Rate
Evaluation of omission errors assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. In both tasks, omission errors occur on trials on which participants do not respond to a go stimulus to which they are supposed to respond. Omission errors are scored from 0 (no omission errors) to 1 (100% omission errors), with lower values indicating better performance.
Time frame: 1 to 3 hours after administration of intervention
Population: Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis. Participants included if they completed at least one task.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Methylphenidate | Go/No-go (GNG) Omission Rate | GNG regular | 0.071 units on a scale | Standard Deviation 0.116 |
| Methylphenidate | Go/No-go (GNG) Omission Rate | GNG reward | 0.040 units on a scale | Standard Deviation 0.055 |
| Placebo | Go/No-go (GNG) Omission Rate | GNG regular | 0.104 units on a scale | Standard Deviation 0.119 |
| Placebo | Go/No-go (GNG) Omission Rate | GNG reward | 0.101 units on a scale | Standard Deviation 0.111 |
Go/No-go (GNG) Response Time Variability
Evaluation of response time variability assessed during the GNG regular and GNG reward tasks. In the GNG tasks, subjects see a series of sports balls and are told to respond to most of the balls (go trials), but not to some specific balls (no-go trials). GNG tasks are identical, except in the rewarded task, correct fast go responses and correct withholding on no-go trials are rewarded with 1 cent and 5 cents respectively. Coefficient of variation (standard deviation / mean) will be calculated for response time in GNG regular and GNG reward tasks separately to account for group differences in mean response time.
Time frame: 1 to 3 hours after administration of intervention
Population: Participants must have good data from both methylphenidate and placebo scan days to be included in this analysis. Participants included if they completed at least one task.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Methylphenidate | Go/No-go (GNG) Response Time Variability | GNG regular | 0.298 coefficient of variation | Standard Deviation 0.104 |
| Methylphenidate | Go/No-go (GNG) Response Time Variability | GNG reward | 0.253 coefficient of variation | Standard Deviation 0.071 |
| Placebo | Go/No-go (GNG) Response Time Variability | GNG regular | 0.344 coefficient of variation | Standard Deviation 0.155 |
| Placebo | Go/No-go (GNG) Response Time Variability | GNG reward | 0.342 coefficient of variation | Standard Deviation 0.146 |